Request a Rep

RhoGAM Half-Life

RhoGAM Has the Longest Half-Life of Any Anti-D Product1,2

  • RhoGAM1 (IM)
    30.9 days mean elimination half-life
  • HyperRHO®3 (IM)
    23-26 days mean elimination half-life
  • Rhophylac®4 (IM)
    18 days mean elimination half-life
  • AABB Guidelines5
    25 days mean elimination half-life
  • ACOG Guidelines6
    23 days mean elimination half-life

Clinical effect of longer half-life has not been studied in head-to-head trials.

AABB = Association for the Advancement of Blood & Biotherapies | ACOG = American College of Obstetricians and Gynecologists | IM = intramuscular

Not all anti-D brands are the same2

Anti-D Comparison Sheet How to Order

Why Half-Life Matters

Not all pregnancies are alike

Pregnant silhouette placeholder

The timing and amount of fetomaternal hemorrhage (FMH) is unpredictable and can present without clinical suspicion7,8

Pregnant silhouette placeholder

There is natural, individual variability in the anti-D half-life9

Pregnant silhouette placeholder

The concentration of anti-D circulating in the maternal bloodstream late in the third trimester varies for each pregnancy9

Pregnant silhouette placeholder

Longer half-life allows for greater residual anti-D in circulation over time10

It’s vital for patients to have sufficient anti-D levels circulating through delivery to reliably protect against Rh sensitization10,12,13

Half-Life Story

RhoGAM Protects Rh-Negative Mothers
Through Delivery

!

Risk of Rh sensitization is highest at delivery6,12,14

20-30

The 300 µg dose of anti-D in RhoGAM administered at 28 weeks is expected to ensure 20-30 µg of residual anti-D remains in maternal circulation at delivery9

>37.5

With the longest half-life of 30.9 days, >12.5% (>37.5 µg) of anti-D could remain in circulation at week 401,2*

*No data, based on internal calculations. No head-to-head studies have compared the half-life or efficacy of all available anti-Ds.

1st

RhoGAM helped set the standards and clinical practice guidelines that are still followed today6

How RhoGAM Works

RhoGAM is a passive Rh antibody that neutralizes any Rh-positive blood that has entered the mother’s circulation1

Illustration showing Rh-positive blood entering mother's circulation

RhoGAM prevents the Rh-negative pregnant mother from making antibodies during pregnancy that could cause hemolytic disease of the fetus and newborn (HDFN) in future pregnancies.1

Illustration of Rh-negative pregnant woman with Rh-positive fetus and antibody formation

As long as the Rh-negative mother receives RhoGAM appropriately during every pregnancy, her babies are at very low risk of developing HDFN.1

Explore Rh Sensitization & HDFN

The Impact of RhoGAM

Since the introduction of RhoGAM in 1968, the incidence of Rh sensitization has decreased dramatically10,12,13

Rh sensitization in Rh-negative mothers
with Rh-positive babies (%)

20 18 16 14 12 10 8 6 4 2 0
Rh sensitization
14-16%
1-2%
<0.1%
Prior to RhoGAM     
RhoGAM at delivery
RhoGAM at 28 weeks and delivery

Stock the Irreplaceable RhoGAM

How to Order
References: 1. RhoGAM Ultra-filtered PLUS [prescribing information]. Kedrion Biopharma Inc. 2024. 2. Aitken SL, Tichy EM. Rh(O)D immune globulin products for prevention of alloimmunization during pregnancy. Am J Health Syst Pharm. 2015;72(4):267-276. 3. HyperRHO S/D Full Dose [prescribing information]. Grifols Therapeutics LLC. 2018. 4. Rhophylac [prescribing information]. CSL Behring LLC. 2020. 5. Lieberman L, Clarke G, Fung M, Lu W, Nester T. AABB Guide to Prenatal and Postnatal Immunohematology Testing. AABB; 2023. Accessed November 13, 2025. https://ebooks.aabb.org/pdfreader/aabb-guide-to-prenatal-perinatal-immunohematology 6. Practice bulletin no. 181: prevention of Rh D alloimmunization. Obstet Gynecol. 2017;130(2):e57-e70. 7. Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion. 1990;30(4):344-357. 8. Pourbabak S, Rund CR, Crookston KP. Three cases of massive fetomaternal hemorrhage presenting without clinical suspicion. Arch Pathol Lab Med. 2004;128(4):463-465. 9. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks’-gestation service program. Can Med Assoc J. 1978;118(6):627-630. 10. Pelikan EW. Half-life. Pharmacology glossary. Boston University Chobanian & Avedisian School of Medicine. Accessed November 13, 2025. https://‌www.bumc.bu.edu/‌ppb/‌pharmacology-glossary/#h 11. Bowman JM. The prevention of Rh immunization. Transfus Med Rev. 1988;2(3):129-150. 12. Hartwell EA; American Society of Clinical Pathologists. Use of Rh immune globulin: ASCP practice parameter. Am J Clin Pathol. 1998;110(3):281-292. 13. Bowman JM. Controversies in Rh prophylaxis: who needs Rh immune globulin and when should it be given? Am J Obstet Gynecol. 1985;151(3):289-294.

Indication

  • RhoGAM® Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] (300 μg) is an immune globulin indicated for use in preventing Rh immunization for pregnancy and other obstetrical conditions in Rh-negative women unless the father or baby is conclusively Rh-negative, e.g., delivery of an Rh-positive baby irrespective of the ABO groups of the mother and baby, any antepartum fetal-maternal hemorrhage (suspected or proven), actual or threatened pregnancy loss at any stage of gestation and ectopic pregnancy.
  • Prevention of Rh immunization in any Rh-negative person after incompatible transfusion of Rh-positive blood or blood products.
  • In the case of postpartum use, RhoGAM is intended for maternal administration. Do not inject the newborn infant.

Important Safety Information

  • RhoGAM is contraindicated in Rh-positive individuals and in patients with a known history of anaphylactic or severe systemic reactions to the administration of human immune globulin products.
  • Severe hypersensitivity reactions may occur with the use of RhoGAM. RhoGAM should be administered in a setting where appropriate equipment, medications such as epinephrine, and personnel trained in the management of hypersensitivity, anaphylaxis, and shock are available.
  • RhoGAM contains a small quantity of IgA. There is a potential risk of hypersensitivity in IgA deficient individuals. Although high doses of intravenous immune globulin containing IgA at levels of 270-720 μg/mL have been given without incident during treatment of patients with high-titer antibodies to IgA, the attending physician must weigh the benefit against the potential risks of hypersensitivity reactions.
  • Products made from human blood may carry a risk of transmitting infectious agents (e.g., viruses, the variant Creutzfeldt-Jakob disease [vCJD] and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent).
  • After administration of Rho(D) immune globulin, a transitory increase of various passively transferred antibodies in the patient’s blood may yield positive serological testing results.
  • The most frequently reported adverse reactions in patients receiving Rho(D) Immune Globulin (Human) products are injection site reactions, such as swelling, induration, redness and mild pain or warmth. Possible systemic reactions are skin rash, body aches or a slight elevation in temperature. Severe systemic reactions include allergic reactions and hemolytic reactions.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information.

This site is intended for residents of the US only.